Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Fesoterodine
2. Toviaz
1. 286930-03-8
2. Toviaz
3. (r)-fesoterodine Fumarate
4. Spm 907
5. Spm 8272
6. Spm-907
7. Spm-8272
8. Fesoterodine Maleate
9. Fesoterodine (fumarate)
10. Eos72165s7
11. (e)-but-2-enedioic Acid;[2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
12. Propanoic Acid, 2-methyl-, 2-[(1r)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl Ester, (2e)-2-butenedioate (1:1)
13. 286930-03-8 (fumarate); 286930-02-7 (free Base)
14. Fesoterodine Fumarate [usan]
15. Unii-eos72165s7
16. Fesoterodine Fumarate [usan:jan]
17. (e)-but-2-enedioic Acid,[2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
18. Toviaz (tn)
19. (r)-fesoterodinefumarate
20. Mls003915638
21. Schembl814971
22. Fesoterodine Fumarate - Toviaz
23. Schembl1993632
24. Chembl1201765
25. Dtxsid00904655
26. Bcpp000231
27. Fesoterodine Fumarate (jan/usan)
28. Fesoterodine Fumarate [mi]
29. Hms3884d11
30. Fesoterodine Fumarate [jan]
31. Amy37611
32. Hy-a0030
33. Bdbm50248002
34. Fesoterodine Fumarate [vandf]
35. Mfcd12756004
36. S2240
37. Fesoterodine Fumarate [mart.]
38. Akos005146248
39. Akos015855886
40. Fesoterodine Fumarate [who-dd]
41. Ac-3486
42. Bcp9000682
43. Ccg-269901
44. Cs-0822
45. Ks-1298
46. 2-((1r)-3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl Isobutyrate
47. Fesoterodine Fumarate [ema Epar]
48. 2-((1r)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl 2-methylpropanoate Hydrogen (2e)-butenedioate (salt)
49. Propanoic Acid, 2-methyl-, 2-((1r)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl Ester, (2e)-2-butenedioate (1:1) (salt)
50. Smr002544691
51. Fesoterodine Fumarate [orange Book]
52. Pf-00695838
53. D08923
54. 930f038
55. A846296
56. Q27277274
57. 2-((1r)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl 2-methylpropanoate Hydrogen(2e)-butenedioate (salt)
58. Fesoterodinefumarate;(r)-fesoterodine Fumarate;2-methylpropanoic Acid 2-[(1r)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl Ester (2e)-2-butenedioate
59. Propanoic Acid,2-methyl ,2-((1r)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl Ester,(2e)-2-butenedioate (1:1)(salt)
Molecular Weight | 527.6 g/mol |
---|---|
Molecular Formula | C30H41NO7 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 13 |
Exact Mass | 527.28830265 g/mol |
Monoisotopic Mass | 527.28830265 g/mol |
Topological Polar Surface Area | 124 Ų |
Heavy Atom Count | 38 |
Formal Charge | 0 |
Complexity | 610 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Toviaz |
PubMed Health | Fesoterodine (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | Toviaz contains fesoterodine fumarate and is an extended-release tablet. Fesoterodine is rapidly de-esterified to its active metabolite (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, or 5-hydroxymethyl tolterodine, which is a musca... |
Active Ingredient | Fesoterodine fumarate |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 8mg; 4mg |
Market Status | Prescription |
Company | Pfizer |
2 of 2 | |
---|---|
Drug Name | Toviaz |
PubMed Health | Fesoterodine (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | Toviaz contains fesoterodine fumarate and is an extended-release tablet. Fesoterodine is rapidly de-esterified to its active metabolite (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, or 5-hydroxymethyl tolterodine, which is a musca... |
Active Ingredient | Fesoterodine fumarate |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 8mg; 4mg |
Market Status | Prescription |
Company | Pfizer |
Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome.
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Urological Agents
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)
G04BD11
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-02-27
Pay. Date : 2012-10-26
DMF Number : 26392
Submission : 2012-08-30
Status : Active
Type : II
NDC Package Code : 47621-025
Start Marketing Date : 2012-08-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-03-14
Pay. Date : 2012-10-26
DMF Number : 26503
Submission : 2012-10-13
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-06-19
Pay. Date : 2012-11-13
DMF Number : 26507
Submission : 2012-10-24
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-24
Pay. Date : 2012-10-31
DMF Number : 26275
Submission : 2012-10-31
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-02-07
Pay. Date : 2012-11-09
DMF Number : 25052
Submission : 2011-06-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26491
Submission : 2012-09-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26498
Submission : 2012-09-28
Status : Inactive
Type : II
NDC Package Code : 50370-0047
Start Marketing Date : 2014-07-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Complete
Rev. Date : 2013-05-06
Pay. Date : 2012-11-02
DMF Number : 26241
Submission : 2012-09-04
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-23
Pay. Date : 2012-11-23
DMF Number : 26345
Submission : 2012-08-17
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26498
Submission : 2012-09-28
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-02-07
Pay. Date : 2012-11-09
DMF Number : 25052
Submission : 2011-06-16
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-26
Pay. Date : 2012-11-29
DMF Number : 26427
Submission : 2012-09-17
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26491
Submission : 2012-09-27
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-24
Pay. Date : 2012-10-31
DMF Number : 26275
Submission : 2012-10-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-03
Pay. Date : 2012-11-23
DMF Number : 26370
Submission : 2012-09-07
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-02-27
Pay. Date : 2012-10-26
DMF Number : 26392
Submission : 2012-08-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-16
Pay. Date : 2012-11-23
DMF Number : 26173
Submission : 2012-10-26
Status : Active
Type : II
Date of Issue : 2022-09-30
Valid Till : 2025-08-08
Written Confirmation Number : WC-0066
Address of the Firm : Plot No 1, Hetero Infrastructure SEZ Ltd., N. Narasapuram, Anakapalli -531081, A...
Date of Issue : 2022-07-11
Valid Till : 2025-08-15
Written Confirmation Number : WC-0022
Address of the Firm : Plot No. 182 to 186, 192-A and 193 to 197 & 212/A,B,C,D Phase-ll, IDA, Pashamyla...
Registrant Name : Sungwoo Chemical Co., Ltd.
Registration Date : 2016-04-29
Registration Number : 4579-12-ND
Manufacturer Name : Alembic Pharmaceuticals Limi...
Manufacturer Address : Plot No.842-843, Village-Karakadi, Taluka-Padra, District-Vadodara - 391 450 Gujarat ...
Registrant Name : Hwail Pharmaceutical Co., Ltd.
Registration Date : 2018-05-31
Registration Number : Su331-16-ND
Manufacturer Name : Hetero Drugs Limited
Manufacturer Address : Plot No. 1, Hetero Infrastructure SEZ Ltd, N.Narasapuram Village, Nakkapalli Mandal, ...
Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2017-12-05
Registration Number : Su258-4-ND
Manufacturer Name : MSN Pharmachem Private Limit...
Manufacturer Address : Plot No.: 212 / A,B,C,D, Phase-II, IDAPashamylaram, Pashamylaram(Village), Patancheru...
Registrant Name : Korea Pfizer Pharmaceutical Co., Ltd.
Registration Date : 2009-06-17
Registration Number : Su189-9-ND
Manufacturer Name : Pfizer Ireland Pharmaceutica...
Manufacturer Address : Ringaskiddy API Plant, Ringaskiddy, County Cork, Ireland
NDC Package Code : 66005-0035
Start Marketing Date : 2011-01-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 66005-0035
Start Marketing Date : 2011-01-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65977-0093
Start Marketing Date : 2008-10-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 71666-005
Start Marketing Date : 2018-09-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 50370-0047
Start Marketing Date : 2014-07-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 50370-0031
Start Marketing Date : 2012-06-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 47621-025
Start Marketing Date : 2012-08-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : HRV Pharma is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...
About the Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with...
About the Company : Beijing Fukangren Biopharmaceutical Technology Co., Ltd. started its drug R&D service in 1999 and is the CRO company with the longest continuous service time in China. Fukangren no...
About the Company : Boryung Pharmaceutical, aiming at the best not the biggest, started from the pharmacy since 1957 and has put a strong presence in Korean market as one of TOP leading pharmaceutical...
About the Company : Dipharma is a leading European manufacturer of Active Pharmaceutical Ingredients that has been developing innovative and proprietary processes since 1949. We support our custome...
About the Company : Flax Laboratories was established by a group of young and experienced professionals with the specific objective to develop and produce complex, small volume, technology driven bulk...
About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...
About the Company : Founded by a group of highly committed Technocrats in year 2009, today Raks Pharma is a partner of choice for pharmaceutical companies across the globe to source Active Pharmaceuti...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz® (fesoterodine fumarate) Extended-Release Tablets, a muscarinic antagonist indicated for the treatment of overactive bladder.
Lead Product(s): Fesoterodine,Inapplicable
Therapeutic Area: Urology Brand Name: Fesoterodine Fumarate-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 07, 2022
Lead Product(s) : Fesoterodine,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz® (fesoterodine fumarate) Extended-Release Tablets, a muscarinic antagonist indicated for the treatment of overactive bladder.
Product Name : Fesoterodine Fumarate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2022
Details:
Alembic Fesoterodine Fumarate-Generic is therapeutically equivalent to Pfizer Fesoterodine Fumarate Extended-Release Tablets indicated for the treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and frequency.
Lead Product(s): Fesoterodine,Inapplicable
Therapeutic Area: Urology Brand Name: Fesoterodine Fumarate-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 02, 2022
Lead Product(s) : Fesoterodine,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alembic Fesoterodine Fumarate-Generic is therapeutically equivalent to Pfizer Fesoterodine Fumarate Extended-Release Tablets indicated for the treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and frequency.
Product Name : Fesoterodine Fumarate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2022
Details:
Undisclosed
Lead Product(s): Fesoterodine,Inapplicable
Therapeutic Area: Urology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 20, 2020
Lead Product(s) : Fesoterodine,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2020
Details:
Undisclosed
Lead Product(s): Fesoterodine,Inapplicable
Therapeutic Area: Urology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 01, 2020
Lead Product(s) : Fesoterodine,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 01, 2020
Details:
Undisclosed
Lead Product(s): Fesoterodine,Inapplicable
Therapeutic Area: Urology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 10, 2019
Lead Product(s) : Fesoterodine,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Fall Prevention in Older Adults With OAB
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2019
Details:
Undisclosed
Lead Product(s): Fesoterodine,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Pfizer Inc | International Collaboration on Repair Discoveries | Vancouver Coastal Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 08, 2016
Lead Product(s) : Fesoterodine,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc | International Collaboration on Repair Discoveries | Vancouver Coastal Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 08, 2016
Details:
Undisclosed
Lead Product(s): Fesoterodine,Inapplicable
Therapeutic Area: Urology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 25, 2015
Lead Product(s) : Fesoterodine,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 25, 2015
Details:
Undisclosed
Lead Product(s): Fesoterodine,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 17, 2015
Lead Product(s) : Fesoterodine,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 17, 2015
Details:
Undisclosed
Lead Product(s): Fesoterodine,Inapplicable
Therapeutic Area: Urology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 31, 2014
Lead Product(s) : Fesoterodine,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 31, 2014
Details:
Undisclosed
Lead Product(s): Fesoterodine,Oxybutynin
Therapeutic Area: Urology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2014
Lead Product(s) : Fesoterodine,Oxybutynin
Therapeutic Area : Urology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2014
CAS Number : 156755-23-6
End Use API : Fesoterodine
About The Company : Malladi Drugs & Pharmaceuticals Ltd was founded in 1980 by microbiologist Mr. M L N Sastry. Within a few years, Malladi established itself as a leader in manufa...
Methyl (±)- 3-(2-(benzyloxy)-5-bromophenyl) -3-ph...
CAS Number : 156755-24-7
End Use API : Fesoterodine
About The Company : Malladi Drugs & Pharmaceuticals Ltd was founded in 1980 by microbiologist Mr. M L N Sastry. Within a few years, Malladi established itself as a leader in manufa...
(±)-3-(2-(Benzyloxy)-5-bromophenyl)-3phenylpropan...
CAS Number : 156755-25-8
End Use API : Fesoterodine
About The Company : Malladi Drugs & Pharmaceuticals Ltd was founded in 1980 by microbiologist Mr. M L N Sastry. Within a few years, Malladi established itself as a leader in manufa...
3-[(1 -phenyl propyl]-4 (phenylmethoxy)benzoic aci...
CAS Number : 156755-35-0
End Use API : Fesoterodine
About The Company : Malladi Drugs & Pharmaceuticals Ltd was founded in 1980 by microbiologist Mr. M L N Sastry. Within a few years, Malladi established itself as a leader in manufa...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
26 Feb 2019
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
50
PharmaCompass offers a list of Fesoterodine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fesoterodine manufacturer or Fesoterodine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fesoterodine manufacturer or Fesoterodine supplier.
PharmaCompass also assists you with knowing the Fesoterodine API Price utilized in the formulation of products. Fesoterodine API Price is not always fixed or binding as the Fesoterodine Price is obtained through a variety of data sources. The Fesoterodine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fesoterodine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fesoterodine, including repackagers and relabelers. The FDA regulates Fesoterodine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fesoterodine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fesoterodine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Fesoterodine supplier is an individual or a company that provides Fesoterodine active pharmaceutical ingredient (API) or Fesoterodine finished formulations upon request. The Fesoterodine suppliers may include Fesoterodine API manufacturers, exporters, distributors and traders.
click here to find a list of Fesoterodine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fesoterodine DMF (Drug Master File) is a document detailing the whole manufacturing process of Fesoterodine active pharmaceutical ingredient (API) in detail. Different forms of Fesoterodine DMFs exist exist since differing nations have different regulations, such as Fesoterodine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fesoterodine DMF submitted to regulatory agencies in the US is known as a USDMF. Fesoterodine USDMF includes data on Fesoterodine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fesoterodine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fesoterodine suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Fesoterodine Drug Master File in Korea (Fesoterodine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Fesoterodine. The MFDS reviews the Fesoterodine KDMF as part of the drug registration process and uses the information provided in the Fesoterodine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Fesoterodine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Fesoterodine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Fesoterodine suppliers with KDMF on PharmaCompass.
A Fesoterodine written confirmation (Fesoterodine WC) is an official document issued by a regulatory agency to a Fesoterodine manufacturer, verifying that the manufacturing facility of a Fesoterodine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Fesoterodine APIs or Fesoterodine finished pharmaceutical products to another nation, regulatory agencies frequently require a Fesoterodine WC (written confirmation) as part of the regulatory process.
click here to find a list of Fesoterodine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fesoterodine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fesoterodine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fesoterodine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fesoterodine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fesoterodine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fesoterodine suppliers with NDC on PharmaCompass.
Fesoterodine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fesoterodine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fesoterodine GMP manufacturer or Fesoterodine GMP API supplier for your needs.
A Fesoterodine CoA (Certificate of Analysis) is a formal document that attests to Fesoterodine's compliance with Fesoterodine specifications and serves as a tool for batch-level quality control.
Fesoterodine CoA mostly includes findings from lab analyses of a specific batch. For each Fesoterodine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fesoterodine may be tested according to a variety of international standards, such as European Pharmacopoeia (Fesoterodine EP), Fesoterodine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fesoterodine USP).